Login to Your Account

Investors on Death Watch?

From Boom to Bust: AFFY's Post-Recall Slide Continues

By Jennifer Boggs
Managing Editor

Monday, May 13, 2013
Practically overnight, Affymax Inc. went from being lauded as a biotech success story and Wall Street darling to become one of the sector's biggest disappointments, and now, according to the latest 10-Q filing, the Palo Alto, Calif.-based firm might be nearing its end.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription